Nonclassic congenital adrenal hyperplasia and bilateral pheochromocytomas in a patient with a germline pathogenic MAX variant Authors: Stefanie Parisien-La Salle, Jonathan Legault, Nadine Dumas, Philippe Arjane, Dominique Trudel, Isabelle Bourdeau Published: 2026 ABSTRACT AbstractWe present the case of a patient with bilateral pheochromocytomas and newly diagnosed nonclassical congenital adrenal hyperplasia (NCCAH). While NCCAH is relatively common, pheochromocytomas are extremely rare. The patient is a 29-year-old woman who was referred for investigation of hirsutism, with a past medical history of hypertension since the age of 18 and precocious pubarche. Magnetic resonance imaging (MRI) showed a right adrenal mass of 4.4 × 4.7 cm and a left adrenal mass of 2.9 × 2.9 cm. Biochemical testing confirmed NCCAH and also revealed elevated 24-hour urinary catecholamines, as well as increased plasma metanephrines. The patient underwent bilateral adrenalectomy, which confirmed the diagnosis of bilateral pheochromocytomas. Genetic testing identified a heterozygous pathogenic germline variant in the MAX gene (deletion exons 1-2) that led to complete loss of expression of MAX in the tumors. Moreover, CYP21A2 gene sequencing revealed a germline homozygous CYP21A2 c.844G> T (p.Val282Leu) pathogenic variant supporting the diagnosis of NCCAH. In summary, this case presents the rare coexistence of bilateral pheochromocytomas with a germline MAX pathogenic variant and NCCAH.Keywords: pheochromocytoma, genetics, nonclassic congenital adrenal hyperplasia Introduction Congenital adrenal hyperplasia (CAH) is an autosomal recessive disease caused by pathogenic variant in the CYP21A2 gene in 95% of cases [1]. Reduced or absent 21-hydroxylase activity results in decreased cortisol production, leading to accumulation of precursors such as 17-hydroxyprogesterone (17-OHP) and increased diversion of these toward androgen synthesis pathway in the zona reticularis [1]. The resulting cortisol deficiency enhances ACTH secretion via loss of negative feedback, further amplifying adrenal androgen excess [2]. Depending on the degree of enzyme deficiency, patients with CAH may present with a phenotype ranging from hirsutism, menstrual irregularities or infertility in nonclassical CAH (NCCAH) to hypotension in the severe salt-wasting form [1]. NCCAH typically presents later in life and should be an important consideration in patients presenting with hirsutism [3]. NCCAH should also be considered when investigating bilateral adrenal masses, with other causes including metastases, bilateral macronodular adrenal hyperplasia and bilateral adenomas [4]. While uncommon, approximately 8% of pheochromocytomas can manifest as bilateral adrenal tumors, and a germline pathogenic variant is found in up to 80% of them [5]. Pheochromocytomas are rare tumors that originate from chromaffin cells in the adrenal medulla [6]. These tumors are usually hormonally active producing excess catecholamines and can cause secondary hypertension [6, 7]. Case presentation We report the case of a 29-year-old Caucasian woman who was referred for hirsutism evaluation. She reported precocious pubarche at age 5, oligomenorrhea and hirsutism since adolescence. She was also diagnosed with hypertension at the age of 18. Her family history included hypertension on her paternal side. Review of systems was positive for headaches, diaphoresis, and palpitations. Diagnostic assessment On physical examination, the patient was hypertensive (168/108 mmHg) with a body mass index of 29.6 kg/m2. She presented with signs of virilization (facial and breast hair) with clitoromegaly and a Ferriman-Gallwey score of 21/36. Magnetic resonance imaging (MRI) showed a right adrenal mass of 4.4 × 4.7 cm and a left adrenal mass of 2.9 × 2.9 cm (Fig. 1). Initial labs showed total testosterone and androstenedione at the upper limit of normal, normal dehydroepiandrosterone sulfate (DHEA-S), and elevated 17-OHP at 18.3 nmol/L (N < 10.7 nmol/L [604 ng/dL; N < 353 ng/dL]). NCCAH was confirmed by a basal 17-OHP level of 17.5 nmol/L (578 ng/dL), with a peak of 70.5 nmol/L (2327 ng/dL) following a 250 mcg cosyntropin stimulation test. The patient was placed on an oral contraceptive for management of hyperandrogenic symptoms. Further biochemical testing revealed a normal 1 mg dexamethasone suppression test and ACTH. Aldosterone to renin ratio was also normal, with nonsuppressed renin. Twenty-four-hour urinary catecholamines, as well as plasma metanephrines and normetanephrines were markedly elevated (Table 1). Fluorine-18 fluorodeoxyglucose positron emission tomography/CT (18F-FDG PET/CT) showed asymmetrical uptake of the adrenal masses with a Maximum Standardized Uptake Value (SUVMax) of 5.4 on the right and 4.6 on the left, and evidence of diffuse brown fat activation (Fig. 2). Gadolinium-enhanced MRI. Gadolinium-enhanced MRI showed the right (A) adrenal mass of 4.4 × 4.7 cm and the left (B) adrenal mass of 2.9 × 2.9 cm, both with T2-hyperintense spots. The adrenal masses are indicated by white arrows. Table 1Laboratory findingsTestSI valueSI normal rangeConverted conventional unitsConventional units normal rangeTotal testosterone2.2 nmol/L0-2.9 nmol/L63.4 ng/dL0-83.6 ng/dLSHBG35 nmol/L22-104 nmol/L3.93 µg/mL2.5-11.7 µg/mLDHEA-S4.2 µmol/L0.8-11.3 µmol/L154.98 µg/dL29.5-417.0 µg/dLAndrostenedione8.4 nmol/L1.6-9.2 nmol/L240.69 ng/dL45.8-263.6 ng/dL17-OHP 18.3 nmol/L <10.7 nmol/L603.96 ng/dL<353.1 ng/dL17-OHP (post ACTH)70.5 nmol/L—2326.7 ng/dL—ACTH5 pmol/L2-11 pmol/L22.73 pg/mL9.1-50.0 pg/mLEpinephrine (24 hours urine) 520 nmol/24h <145 nmol/24h95.34 µg/24 hours<26.6 µg/24 hoursNorepinephrine (24 hours urine) 31 175 nmol/24h <650 nmol/24h5271.39 µg/24 hours<109.9 µg/24 hoursMetanephrines (24 hours urine) 1270 nmol/24h <370 nmol/24h250.49 µg/24 hours<73.0 µg/24 hoursNormetanephrines (24 hours urine) 24 260 nmol/24h <600 nmol/24h4443.22 µg/24 hours<109.9 µg/24 hoursDopamine (24 hours urine) 16 885 nmol/24h <4520 nmol/24h2588.14 µg/24 hours<692.8 µg/24 hoursPlasma Metanephrines 1.38 nmol/L <0.50 nmol/L——Plasma normetanephrines 36 nmol/L <0.9 nmol/L——Calcium (serum) 2.67 mmol/L 2.17-2.56 mmol/L10.68 mg/dL8.7-10.2 mg/dL24 hours calcium excretion 9.9 mmol/24h 2.5-7.5 mmol/24h396.0 mg/24 hours100-300 mg/24 hoursParathyroid hormone 7.1 pmol/L 1.4-6.8 pmol/L66.98 pg/mL13.2-64.2 pg/mL25OH-vitamin D44 nmol/L35-150 nmol/L17.63 ng/mL14.0-60.1 ng/mLBolded values indicate results outside the specified SI reference range.Abbreviations: 17-OHP, 17-hydroxyprogesterone; 25OH-vitamin D, 25-hydroxyvitamin D; ACTH, adrenocorticotropic hormone; DHEA-S, dehydroepiandrosterone sulfate; PTH, parathyroid hormone; SHBG, Sex hormone binding globulin; SI, International System of Units. Laboratory findings Bolded values indicate results outside the specified SI reference range. Abbreviations: 17-OHP, 17-hydroxyprogesterone; 25OH-vitamin D, 25-hydroxyvitamin D; ACTH, adrenocorticotropic hormone; DHEA-S, dehydroepiandrosterone sulfate; PTH, parathyroid hormone; SHBG, Sex hormone binding globulin; SI, International System of Units. 18F-FDG PET scan. 18F-FDG PET scan showed asymmetrical uptake of the 2 adrenal masses with a SUVMax of 5.4 on the right (A) 4.6 on the left (B). The adrenal masses are indicated by white arrows. The patient also presented with labs suggestive of primary hyperparathyroidism. Her serum calcium was elevated at 2.67 mmol/L (N 2.17-2.56 mmol/L [10.68 mg/dL; N 8.68-10.24 mg/dL]), as was her parathyroid hormone (PTH) (7.1 pmol/L; N 1.4-6.8 pmol/L [67.0 pg/mL; N 13.2-64.2 pg/mL]). Her 24 hours-urinary calcium excretion was elevated at 9.9 mmol/24 hours (N 2.5-7.5 mmol/24 hours [396 mg/24 hours; N 100-300 mg/24 hours]) with a normal to low 25-OH vitamin D level (44 nmol/L; N 35-150 nmol/L [17.6 ng/mL; N 14.0-60.1 ng/mL]). Phosphate, albumin and calcitonin levels were normal. Although imaging was performed with Tc-99 m sestamibi parathyroid scintigraphy, results were not interpretable due to the hyperstimulation of the brown fat caused by catecholamines hypersecretion [8, 9]. Treatment The patient underwent bilateral adrenalectomy, and histopathological analysis confirmed bilateral pheochromocytomas with areas of necrosis, subcapsular vascular invasion, and a diffuse growth/large nest pattern involving more than 10% of the tumor,features that could be suggestive of aggressive behavior (PASS >4). No significant abnormalities were identified in the adjacent adrenal cortex. After genetic counseling, a multigene panel of 14 pheochromocytomas and paragangliomas (PPGL)-related genes (SDHA, SDHAF2, SDHB, SDHC, SDHD, RET, VHL, FH, NF1, MAX, TMEM127, EGLN1, KIF1B, MEN1) (Invitae, San Francisco, CA, USA) was used to analyze the patient's leukocyte DNA. A heterozygous germline pathogenic variant in the MAX gene (deletion exons 1-2) was identified. This deletion includes the initiator codon. Moreover, CYP21A2 gene sequencing revealed a germline homozygous CYP21A2 c.844G> T (p.Val282Leu) pathogenic variant supporting the diagnosis of NCCAH. Immunohistochemical analysis (IHC) was performed following a standard protocol, as previously described [10], with methodological details summarized below. Following standard deparaffinization, 4 µm-thick sections of the formalin-fixed paraffin-embedded (FFPE) tissues were stained using the automated VENTANA Benchmark XT stainer (Ventana Medical Systems, Roche, Rotkreuz, Switzerland). Antigen retrieval was conducted using Cell Conditioning #1 solution (Tris-EDTA buffer, pH 7.8; Ventana Medical System Inc., Oro Valley, AZ, USA) for 60 minutes at 95 °C. Rabbit polyclonal anti-MAX antibody (diluted at 1/1000; ab101271, Abcam Inc., Cambridge, UK) was then added to the slides and incubated for 60 minutes at 37 °C. Visualization was achieved using the UltraView DAB Detection Kit (Ventana Medical System Inc.), followed by counterstaining with hematoxylin and bluing reagent (Ventana Medical System Inc.). An external positive control included a pheochromocytoma specimen with a negative multigene panel. Images were analysed using the Aperio Image Scope software (Leica Biosystems, Buffalo Grove, IL, USA). The patient's pheochromocytoma tissue showed negative nuclear staining to MAX, while the adjacent medulla parenchyma displayed strong positivity to MAX antibody (Fig. 3). Immunohistochemical and pathologic characterization of the resected pheochromocytomas. Immunohistochemical detection of MAX expression in formalin-fixed paraffin-embedded resected tissues from the patient, using MAX rabbit polyclonal antibody (ab101271) at 1/1000 (1 µg/mL). Both right (A) and left (B) adrenal gland pheochromocytomas displayed negative nuclear staining to the MAX antibody (arrows), while adjacent adrenal cortex demonstrated positivity to the MAX antibody (arrowheads). Dotted black lines delineate the boundary between the tumor and the adjacent adrenal cortex. Scale bar: 200 µm. Cascade testing was initiated in the patient's first-degree relatives, including 1 of 2 siblings and both parents. Genetic analysis confirmed that the MAX exon 1-2 deletion was indeed de novo, as the deletion was absent in both parents. The patient's brother was tested to rule out the possibility of parental germline mosaicism, which can result in transmission of a pathogenic variant despite negative parental testing [11], and he was also negative for the MAX deletion. CYP21A2 testing in both parents confirmed that each is a heterozygous carrier of the c.844G> T pathogenic variant. No parental consanguinity was reported. The patient's brother was also found to be a CAH carrier. To our knowledge, the patient's other sibling has not been evaluated. Outcome and follow-up Following surgery, the patient was placed on replacement hydrocortisone and fludrocortisone. Her catecholamines, calcium, and PTH levels normalized after 1-month post-op. We now have a 12-year post-op follow-up time, and patient has not had a recurrence of her pheochromocytoma and her calcium levels have remained normal. Discussion This case presents the rare coexistence of bilateral pheochromocytomas with a germline MAX pathogenic variant and NCCAH. In the literature, we identified only 2 reported cases of functional pheochromocytomas in patients with classical CAH and none with NCCAH [12, 13]. Of the 2 reported pheochromocytoma/CAH cases, one was incidentally discovered and had negative germline testing for PPGL susceptibility genes, whereas the other did not report any genetic testing [12, 13]. In our patient, the driver of tumorigenesis for the bilateral pheochromocytomas is the presence of the pathogenic germline MAX variant. MAX is a cluster 2 tumor suppressor gene involved in chromatin remodeling and transcription regulation via MYC/MAX/MAD networks, in which MYC functions as a transcriptional activator and MAD proteins act as transcriptional repressors [14, 15]. Germline pathogenic variants in MAX are implicated in a small subset of PPGLs, typically presenting in younger individuals with a high prevalence of bilateral pheochromocytomas [14, 16]. In some cases, MAX-related PPGLs have also been associated with other neuroendocrine tumors [17]. Large deletions are relatively less common, accounting for <15% of MAX mutations, while most pathogenic variants are nonsense or missense mutations, predominantly located in exons 3 and 4 [14]. These alterations disrupt the MAX protein's basic helix-loop-helix leucine zipper domain, impairing its dimerization with MYC or MAD. This disruption impairs transcriptional regulation of MYC target genes, leading to dysregulated cell proliferation and tumorigenesis [17]. Another noteworthy aspect of this case is the presence of primary hyperparathyroidism, which was identified prior to the bilateral adrenalectomy. Although the association of pheochromocytomas with hyperparathyroidism is not rare and is well described in Multiple Endocrine Neoplasia type 2A (MEN2A) syndrome [18], in our patient, hyperparathyroidism appeared to be cured with bilateral adrenalectomy. This raises the question of ectopic PTH secretion by the pheochromocytomas. This association has been previously described with PTH [19] and PTH-related protein [20]. For our case, immunohistochemistry for PTH staining was not available to provide further insight. Importantly, this case underscores the critical role of genetic testing in adrenal pathologies. Genetic analysis led to the identification of a driver pathogenic variant in the MAX gene, predisposing the patient to pheochromocytomas, and a pathogenic variant in CYP21A2 confirming the diagnosis of NCCAH. Pheochromocytoma susceptibility genes follow an autosomal dominant inheritance pattern, warranting familial screening of index cases [6]. In contrast, CAH is inherited in an autosomal recessive manner [1], and identifying carriers within the proband's family is particularly relevant in the context of fertility and preconception counseling, including assessment of the risk of affected offspring if the partner is also a carrier. CYP21A2 and MAX are functionally unrelated genes involved in distinct biological pathways and no causal genetic relationship between NCCAH and MAX-related pheochromocytoma predisposition is currently known. Nevertheless, it remains possible that these 2 pathologies may interact at a biological level. The androgen levels measured during the patient's evaluation at the adult endocrinology clinic were normal at that time; however, those levels do not capture the full range of fluctuations she may have experienced throughout her life, during which clear chronic signs of virilization were evident. While the MAX pathogenic variant is the primary driver of pheochromocytoma tumorigenesis, expression of ectopic progesterone and androgen receptors has been reported in a subset of these tumors [21]. Although recent in vitro data do not support a proliferative effect of progesterone, testosterone, estradiol, or DHEA-S on PPGLs [21], we hypothesize that chronic exposure to elevated androgens or progesterone may nevertheless engage their respective receptors and modulate PPGL secretion or proliferation in this case. However, receptor expression was not assessed in the present case and any potential interaction between androgen exposure and pheochromocytoma biology therefore remains speculative. In summary, though pheochromocytomas and NCCAH arise from distinct germline pathogenic variant and their coexistence in the same patient is very likely coincidental, there remains a possibility that these 2 distinct pathologies could influence one another through specific receptor activity. Learning points Biochemical and imaging workup is essential in young patients with signs of virilization or hypertension. Biochemical and imaging workup is essential in young patients with signs of virilization or hypertension. Bilateral pheochromocytomas with concomitant NCCAH is an exceptionally rare association but may coexist. Bilateral pheochromocytomas with concomitant NCCAH is an exceptionally rare association but may coexist. Genetic testing can aid in diagnosing distinct adrenal pathologies and guide appropriate familial screening. Genetic testing can aid in diagnosing distinct adrenal pathologies and guide appropriate familial screening. Acknowledgments We would like to thank the past and current chiefs of the Genetic Division at the CHUM, Dr Pavel Hamet and Dr Zaki El-Haffaf, for their support, as well as all the members of the Genetics Division. We would like to thank Dr Latour and Feryel Azzi in Pathology. Access to Dr Mame-Kany Diop's expertise was possible thanks to the TransMedTech Institute and its primary funding partner, the Canada First Research Excellence Fund. Contributor Information Stefanie Parisien-La Salle, Division of Endocrinology, Department of Medicine and Research Center, Centre hospitalier de L’Université de Montréal (CHUM), Québec, Canada H2X 0C1. Jonathan Legault, Division of Endocrinology, Department of Medicine and Research Center, Centre hospitalier de L’Université de Montréal (CHUM), Québec, Canada H2X 0C1. Nadine Dumas, Division of Genetics, Department of Medicine and Research Center, CHUM, Québec, Canada H2X 0C1. Philippe Arjane, Division of Urology, Department of Surgery, Hôpital Charles-Lemoyne, Centre Hospitalier de L’Université de Sherbrooke, Québec, Canada J4V 2H1. Dominique Trudel, Department of Pathology, CHUM, Québec, Canada H2X 0C1. Isabelle Bourdeau, Division of Endocrinology, Department of Medicine and Research Center, Centre hospitalier de L’Université de Montréal (CHUM), Québec, Canada H2X 0C1; Division of Genetics, Department of Medicine and Research Center, CHUM, Québec, Canada H2X 0C1. Contributors Each author made individual contributions to the work. S.P.-L.S., I.B., and J.L. were involved in diagnosis and management. P.A. was responsible for the patient's surgery. N.D. was responsible for genetic testing. D.T. was involved in the histopathology and preparation of histology images. S.P.-L.S. was involved in manuscript submission. All authors reviewed and approved the final draft. Funding This study was supported in part by salary grants from Fonds de recherche du Québec—Santé (FRQS) (I.B., D.T.) and Formation de recherche pour les résidents-Résidence complémentaire en recherche: phase 1 FRQS (S.P.-L.S.). Financial support was also received from the Cancer Research Society (I.B.), and the Centre de Recherche du CHUM received support from the FRQS. Disclosures The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Informed patient consent for publication Signed informed consent obtained directly from the patient. Data availability Data sharing is not applicable to this article as no datasets were generated or analyzed in the current study. References Associated Data Data Availability Statement Data sharing is not applicable to this article as no datasets were generated or analyzed in the current study.